MAnagement of High Bleeding Risk Patients Post Bioresorbable Polymer Coated STEnt Implantation With an Abb Reviated Versus Prolonged DAPT Regimen ID: NCT03023020 The study compares two lengths of medication therapy (a shortened versus a prolonged dual antiplatelet therapy) in order to prevent...
Evaluation of a Sirolimus Eluting Bioadaptor as Compared to a Zotarolimus Eluting Stent in De novo Native Coronary Arteries ID: NCT04192747 The objective of this study is to verify the safety and efficacy of the investigational device (ELX1805J) for the treatment of ischemic heart disease due to de...
A Prospective Study of the BioFreedom™ Biolimus A9™ Drug Coated Stent in Patients at High Risk for Bleeding Study Details | NCT02843633 | LEADERS FREE II: BioFreedom™ Pivotal Study | ClinicalTrials.gov
LEADERS-FREE is a randomized double-blinded trial which was designed to assess the combination of a short course (1 month) of DAPT with either the BioFreedom DCS (drug-coated stent) or the Gazelle BMS in patients with at least one of several criteria for an increased bleeding risk: advanced age...
TARGET FIRST is a prospective, international, multicentre, open-label, randomized (1:1) post-market study to evaluate a modified Anti-Platelet Therapy associated with low-dose rapamycin DES Firehawk in Acute Myocardial Infarction Patients treated with complete revascularization strategy. The...
Single-arm, Prospective, Open label, All Comers, Multicenter Registry. The objective is to collect and evaluate clinical data regarding the safety and performance of the Support C in a real-world setting (in clinical routine)
Single-arm, Prospective, Open label, All Comers, Multicenter Registry. The objective is to assess safety and performance of EucaLimus, a sirolimus eluting PTCA stent system, in a prospective study as part of the manufacturer‘s post-market surveillance program
ABILITY DIABETES GLOBAL is a prospective, multi-center, multinational, randomized, open label (follow-ups blinded), 2-arm parallel groups study. The objective is to compare in diabetic patients eligible for percutaneous coronary intervention (PCI) with minimal exclusion criteria, the efficacy and...
A Prospective Randomized (1:1), Multi-center, International, Open label Clinical trial. The objective is to demonstrate non-inferiority for Target Vessel Failure (TVF) of a treatment strategy with first line SELUTION SLR Drug Eluting Balloon (DEB) plus provisional Drug Eluting Stent (DES) vs...
SAITO1B is prospective, single arm, First-In-Human study. The objective is to assess the feasibility and safety of the TaviPilot augmented reality guidance software during TAVI procedures, aiming to improve valve positioning precision and, implicitly, reduce implantation depth variations in patients...
